Alfuzosin Hcl

證據等級: L5

預測適應症: 0 個

Alfuzosin HCL: Repurposing Evaluation — Insufficient Data to Complete Assessment

One-Sentence Summary

Alfuzosin HCL is a pharmaceutical compound; however, this Evidence Pack contains no original indication data, no TxGNN-predicted new indications, and no safety information. Without predicted indications or mechanism data, a standard repurposing evaluation cannot be completed at this stage. All core inputs are missing — a Hold decision is mandatory until data collection is complete.

Quick Overview

Item	Content
Original Indication	Not available in this Evidence Pack
Predicted New Indication	None — no predictions generated
TxGNN Prediction Score	Not available
Evidence Level	L5 (no studies; no model prediction output)
Singapore Market Status	Not marketed
Number of Registrations	0
Recommended Decision	Hold

Why a Full Assessment Cannot Be Completed

This Evidence Pack is missing all three inputs required to complete a repurposing analysis:

No mechanism of action (MOA) data. The DrugBank query returned a result (result_count: 1), but no MOA was extracted. This blocks the mechanistic rationale section entirely.
No predicted indications. The predicted_indications array is empty, meaning TxGNN did not produce — or did not successfully populate — any repurposing candidates for Alfuzosin HCL in this run. Without a target indication, the clinical trial evidence, literature evidence, and prediction rationale sections cannot be written.
No approved indication on record. The original indication list is empty and the Singapore HSA database shows zero registrations, so even the drug's established therapeutic role cannot be confirmed from this pack alone.

Currently, detailed mechanism of action data is not available. Based on its INN suffix (-zosin), Alfuzosin likely belongs to the alpha-1 adrenergic receptor blocker class — but this must be verified from DrugBank before being used in any evaluation.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Singapore Market Information

Alfuzosin HCL has zero HSA registrations in Singapore and is listed as not marketed. There are no authorisation records to display.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack is missing predicted indications, approved indications, mechanism of action, and all safety data — the minimum viable inputs for a repurposing evaluation are not present, and proceeding would produce a report with no evidential basis.

To proceed, the following is needed:

Re-run TxGNN prediction for Alfuzosin HCL and confirm that predicted_indications is populated before generating the next report version
Retrieve DrugBank record — the query log shows a successful hit (result_count: 1); extract drugbank_id, MOA, drug categories, and toxicity data
Confirm original approved indication(s) — check TFDA, EMA, or FDA label for the registered indication (likely benign prostatic hyperplasia based on drug class, but must be verified)
Retrieve safety information — download and parse the prescribing information PDF to extract warnings, contraindications, and drug-drug interactions
Verify Singapore HSA status — confirm whether the drug is intentionally absent from the Singapore market or whether the query failed to match the correct entry (consider searching by brand name or partial INN)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.